Mount Yale Investment Advisors LLC bought a new stake in Eli Lilly And Co (NYSE:LLY) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,761 shares of the company’s stock, valued at approximately $6,248,000. Eli Lilly And Co comprises approximately 1.3% of Mount Yale Investment Advisors LLC’s investment portfolio, making the stock its 19th largest holding.
Other institutional investors have also recently bought and sold shares of the company. Avestar Capital LLC acquired a new stake in Eli Lilly And Co in the fourth quarter valued at $100,000. Stelac Advisory Services LLC acquired a new stake in Eli Lilly And Co in the first quarter valued at $134,000. Silvant Capital Management LLC acquired a new stake in Eli Lilly And Co in the first quarter valued at $150,000. McKinley Carter Wealth Services Inc. acquired a new stake in Eli Lilly And Co in the first quarter valued at $153,000. Finally, Truewealth LLC acquired a new stake in Eli Lilly And Co in the fourth quarter valued at $186,000. 76.01% of the stock is currently owned by institutional investors.
Several analysts have weighed in on the company. DZ Bank reissued a “hold” rating on shares of Eli Lilly And Co in a report on Friday. Credit Suisse Group upped their target price on Eli Lilly And Co from $82.00 to $84.00 and gave the company an “underperform” rating in a report on Thursday. JPMorgan Chase & Co. set a $100.00 target price on Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, June 11th. Cantor Fitzgerald assumed coverage on Eli Lilly And Co in a report on Thursday, June 7th. They issued an “overweight” rating and a $100.00 target price on the stock. Finally, Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a report on Wednesday, May 30th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $94.00.
NYSE LLY traded up $0.03 during trading hours on Monday, hitting $85.95. 248,779 shares of the company’s stock were exchanged, compared to its average volume of 3,577,661. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a market capitalization of $93.26 billion, a PE ratio of 20.08, a price-to-earnings-growth ratio of 1.46 and a beta of 0.29. The company has a current ratio of 1.41, a quick ratio of 1.01 and a debt-to-equity ratio of 0.64.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.21. Eli Lilly And Co had a return on equity of 35.37% and a net margin of 4.82%. The firm had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.51 billion. During the same period in the prior year, the business posted $0.98 earnings per share. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities analysts predict that Eli Lilly And Co will post 5.15 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be given a dividend of $0.5625 per share. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 annualized dividend and a yield of 2.62%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $86.65, for a total transaction of $15,597,000.00. Following the transaction, the insider now directly owns 122,050,804 shares in the company, valued at $10,575,702,166.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Susan Mahony sold 5,165 shares of the stock in a transaction dated Friday, April 13th. The stock was sold at an average price of $80.14, for a total value of $413,923.10. Following the transaction, the senior vice president now owns 45,652 shares in the company, valued at $3,658,551.28. The disclosure for this sale can be found here. Insiders have sold 987,464 shares of company stock worth $82,748,955 over the last quarter. 0.11% of the stock is currently owned by company insiders.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.